Глобальный рынок генного редактирования CRISPR – тенденции отрасли и прогноз до 2031 года

Анализ и размер рынка генного редактирования CRISPR

Рынок редактирования генов CRISPR переживает стремительный рост и готов трансформировать сферы биотехнологии, здравоохранения и сельского хозяйства. Рынок в первую очередь обусловлен растущим спросом на инновационные методы лечения генетических нарушений, рака и других заболеваний. Технология CRISPR предлагает точный и эффективный способ редактирования генов, что позволяет разрабатывать целевые методы лечения, которые могут произвести революцию в лечении различных заболеваний. Применение CRISPR в сельском хозяйстве расширяется, включая его использование для разработки сельскохозяйственных культур с повышенной урожайностью и устойчивостью к вредителям и болезням, что еще больше стимулирует рост рынка.

Объем мирового рынка редактирования генов CRISPR оценивался в 1,41 млрд долларов США в 2023 году и, по прогнозам, достигнет 11,36 млрд долларов США к 2031 году со среднегодовым темпом роста 29,80% в прогнозируемый период с 2024 по 2031 год. Помимо информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают глубокий экспертный анализ, эпидемиологию пациентов, анализ конвейера, анализ цен и нормативно-правовую базу.

Область отчета и сегментация рынка       

Определение рынка

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) — революционная технология редактирования генов, которая позволяет ученым вносить точные изменения в ДНК организмов. Она основана на естественном процессе, используемом бактериями для защиты от вирусов. Технология CRISPR произвела революцию в генетических исследованиях и имеет потенциал для лечения генетических заболеваний, разработки новых методов лечения и повышения урожайности.          

Динамика рынка генного редактирования CRISPR

Драйверы

• Растущий спрос на персонализированную медицину  

Персонализированная медицина направлена ​​на предоставление более целенаправленных и эффективных методов лечения различных заболеваний с учетом уникального генетического состава каждого пациента. Технология CRISPR играет решающую роль в этом подходе, позволяя вносить точные изменения в геном, что позволяет исправлять генетические мутации, связанные с заболеваниями. Эта способность адаптировать методы лечения к индивидуальным генетическим профилям имеет потенциал для революции в здравоохранении за счет улучшения результатов лечения и снижения побочных эффектов, что способствует все большему внедрению редактирования генов CRISPR в медицинскую практику.    

• Стремительное развитие технологии CRISPR

Одной из основных областей прогресса является разработка более точных систем CRISPR, которые могут воздействовать на определенные области генома с большей точностью, снижая риск нецелевых эффектов. Кроме того, усовершенствования методов доставки упростили введение компонентов CRISPR в клетки, повысив эффективность редактирования генов. Эти достижения значительно расширили потенциальные возможности применения технологии CRISPR, сделав ее ценным инструментом в различных областях, включая разработку новых методов лечения, изучение функций генов и создание генетически модифицированных организмов с полезными признаками. Постоянное усовершенствование технологии CRISPR, включая улучшение специфичности и эффективности, стимулирует рост рынка.

Возможности

• Expansion of Therapeutic Applications  

CRISPR technology has shown promise in treating a wide range of genetic disorders, infectious diseases, and cancer by targeting specific genes associated with these conditions. In the field of genetic disorders, CRISPR has the potential to correct disease-causing mutations, offering a potential cure for genetic diseases that were previously untreatable. In infectious diseases, CRISPR can be used to target and eliminate viral or bacterial DNA, providing a new approach to combating antibiotic-resistant pathogens.  The expansion of CRISPR-based therapeutic applications represents a significant opportunity for market growth.     

• Development of Novel Therapies    

The development of gene therapies that use CRISPR to correct genetic mutations underlying various diseases has shown promise in early clinical trials for conditions such as sickle cell anemia and beta-thalassemia. Another area of innovation is the use of CRISPR in the development of personalized cancer therapies. By targeting specific genetic mutations in a patient's tumor cells, CRISPR can help tailor treatments to individual patients, potentially improving treatment outcomes. CRISPR technology is driving the development of novel therapies that were previously not possible, opening up new opportunities in the pharmaceutical and biotechnology industries.

Restraints/Challenges

• Ethical and Regulatory Challenges        

The ability to make heritable changes to the genome raises complex ethical questions regarding the potential misuse of the technology, the creation of designer babies, and the alteration of future generations' genetic makeup. These concerns have led to calls for strict regulations and guidelines governing the use of CRISPR in human germline editing. In addition, regulatory challenges, such as the need for clear approval processes and oversight mechanisms, further complicate the development and commercialization of CRISPR-based products, creating significant challenges for the market.

• Intellectual Property Disputes

 The CRISPR-Cas9 technology is based on groundbreaking research that has led to the filing of numerous patents by different research groups and institutions. These disputes have resulted in legal battles over patent rights, which could impact the market landscape and slow down the development and commercialization of CRISPR-based products. Ongoing intellectual property disputes over key CRISPR patents represent another challenge for the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In February 2023, Vertex hinted at its launch strategy for the first CRISPR gene editing therapy, pending FDA approval. The therapy, developed in partnership with CRISPR Therapeutics, targets a specific group of patients with severe disease, estimated to be around 32,000 individuals in the U.S. and Europe. These patients are concentrated in specific geographic regions and typically experience frequent vaso-occlusive crises or depend on regular blood transfusions, necessitating multiple hospitalizations annually              
• In March 2021, Setsuro Tech, a Japanese biotech company, secured a patent for CRISPR-Cas9 technology from ERS Genomics, based in Dublin. Setsuro Tech is leveraging this advanced technology to develop animal and cell models, showcasing its commitment to innovative research in the field

CRISPR Gene-Editing Market Scope

The market is segmented on the basis of therapeutic application, application, technology, services, products, and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapeutic Application

• Oncology
• Autoimmune or Inflammatory

Application

• Genome Engineering
• Disease Models
• Functional Genomics
• Others

Technology

• CRISPR or Cas9
• Zinc Finger Nucleases
• Others

Services

• Design Tools
• Plasmid and Vector
• Cas9 and g-RNA
• Delivery System Products
• Others

Products

• GenCrispr or Cas9 kits
• GenCrispr Cas9 Antibodies
• GenCrispr Cas9 Enzymes
• Others

End-Users

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations
• Others

CRISPR Gene-Editing Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, therapeutic application, application, technology, services, products, and end-users as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to substantial investments from biotechnology and pharmaceutical companies. In addition, the region's expanding healthcare infrastructure is expected to enhance market growth during the forecast period further.     

Asia-Pacific is expected to witness significant growth during the forecast period due to the rising per capita income in the region. Moreover, early access to authorized therapies is anticipated to drive market growth in Asia-Pacific in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and CRISPR Gene-Editing Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Applied StemCell (U.S.)
• ACEA BIO (U.S.)
• Synthego (U.S.)
• Thermo Fisher Scientific (U.S.)
• GenScript (China)
• Addgene (U.S.)
• Merck KGaA (Germany)
• Intellia Therapeutics, Inc. (U.S.)
• Cellectis (France)
• Precision Biosciences (U.S.)
• Caribou Biosciences, Inc. (U.S.)
• Transposagen Biopharmaceuticals, Inc. (U.S.)
• OriGene Technologies, Inc. (U.S.)
• Новартис АГ (Швейцария)
• New England Biolabs (США)
• Rockland Immunochemicals Inc. (США)
• ToolGen, Inc. (Южная Корея)
• TAKARA BIO INC. (Япония)
• Agilent Technologies, Inc. (США)
• Abcam plc (Великобритания)
• CRISPR Therapeutics AG (Швейцария)

SKU-46288